Aerogen has introduced a new nebulizer that is integrated into the Maquet SERVO-i ventilator. The high efficiency vibrating mesh Aeroneb nebulizer can be retrofitted to existing ventilators or purchased with new units. Aerogen CEO John Power commented “The potential for Aerogen’s advanced technology to reach the Maquet customer base is a very exciting one. We were … [Read more...] about New nebulizer integrated into ventilator
News
Relequa teams up with Elite Measurement
UK laboratory equipment company Elite Measurement Solutions is now distributing the Relequa Moisture Profiling System which determines equilibrium relative humidity for the optimization of dry powder and other formulations. Moisture profiling can provide information relevant to dry powder stability and aerosolization. The two companies will share a booth at DDL 22 in … [Read more...] about Relequa teams up with Elite Measurement
Aradigm gets additional funding from existing shareholders
Existing shareholders have agreed to purchase additional Aradigm Corporation common stock for a total of $4.75 million. The three shareholders will pay $0.19 per share for 25 million shares. The net proceeds for Aradigm after fees and expenses should be about $4.4 million. "We are very pleased for the support demonstrated by our shareholders in this private … [Read more...] about Aradigm gets additional funding from existing shareholders
European marketing approval for single dose Instanyl nasal spray
The European Commission has granted marketing authorization for Nycomed's single dose Instanyl fentanyl nasal spray for the treatment of breakthrough pain in cancer patients. A multi-dose Instanyl product was approved by the EC in 2009 and is marketed in 50, 100, and 200 mcg dose versions. The single dose Instanyl will be available in the same dosages. "The launch … [Read more...] about European marketing approval for single dose Instanyl nasal spray
FDA approves indacaterol
The FDA has approved Novartis's Arcapta Neohaler with a 75 mcg once-daily dose of indacaterol for the treatment of COPD. Novartis sells an indacaterol inhaler in Europe as the Onbrez Breezhaler. The company plans to launch the Arcapta Neohaler in the US in the first quarter of 2012. An FDA advisory committee recommended approval of the 75 mcg dose in March 2011 … [Read more...] about FDA approves indacaterol
FDA approval for fentanyl nasal spray
The FDA has approved Archimedes Pharma's Lazanda fentanyl nasal spray for the treatment of breakthrough pain in cancer patients 18 years old and older. The product is already marketed in five European countries, where it is called PecFent. “Lazanda is an important new option for patients with cancer who experience excruciating breakthrough pain," said Jeffrey … [Read more...] about FDA approval for fentanyl nasal spray
Forest and Almirall submit NDA for aclidinium bromide
Forest Laboratories and Almirall have submitted a new drug application to the FDA for their inhaled aclidinium bromide, a dry powder long-acting inhaled antimuscarinic agent for the treatment of COPD. Forest has licensed the US rights to the product; Almirall retains the rights elsewhere. The aclidinium bromide formulation is delivered via a multi-dose DPI and will … [Read more...] about Forest and Almirall submit NDA for aclidinium bromide
Phase 3 study shows NVA237 as effective as tiotropium
NVA237, a glycopyrronium bromide dry powder formulation licensed by Novartis from Sosei and Vectura has met its primary endpoint in the Phase 3 GLOW2 trial. According to Sosei, the study showed that NVA237 had similar efficacy to tiotropium and provided significant improvement in lung function when given once a day to COPD patients with moderate-to-severe … [Read more...] about Phase 3 study shows NVA237 as effective as tiotropium
Prosonix obtains additional financing
Particle engineering company Prosonix has secured £11.4M from a group of investors led by French venture company Ventech. Other investors involved in this round of financing include Entrepreneurs Fund, Quest for Growth, and Solon Ventures, all of which are already invested in Prosonix, plus new investor Gilde Healthcare Partners. The company plans to use the money … [Read more...] about Prosonix obtains additional financing
Pulmatrix announces new appointments
Pulmatrix, which recently launched its new iSperse dry powder delivery system, has announced the promotion of Robert Clarke to Chief Scientific Officer (CSO) and VP of Research and Development. In addition, the company has added 8 members to its scientific advisory board. Clarke has been leading research efforts at Pulmatrix since 2004 after leaving Alkermes. … [Read more...] about Pulmatrix announces new appointments